




TARGET > CANCER

2015 ANNUAL REPORT

 **ACGT** ALLIANCE FOR
CANCER GENE THERAPY

Discovering new ways to treat and defeat cancer

THE LINEAR SEQUENCE OF THE LETTERS A|C|G|T COMPRISES THE GENETIC CODE



ALLIANCE FOR CANCER GENE THERAPY

is the only charitable organization in the nation dedicated exclusively to funding and fostering research into cell and gene therapies for cancer.

OUR MISSION is to seek out and support revolutionary scientific research into the causes, treatment and prevention of all types of cancer using cells and genes as medicine.

TO THIS END we fund and monitor studies and trials that meet the highest possible standards, educate the public on the potential for targeted medicine, and facilitate greater collaboration among the scientific and philanthropic communities to promote progress.





Call the science precision medicine, personalized therapeutics, or targeted treatments: cell and gene therapies take aim at cancer cells to destroy them and protect against relapse. These remedies are directed to the cancer, and only the cancer, without damage to other parts of the body. The body does not have to be poisoned or surgically opened to combat cancer.

Think of these therapies as the ancient sport of archery – bows and arrows pointed dead center at the target. Shooting for the bull’s eye every time.

HOW?

Molecular medicine is not sport, rather a technology-based re-engineering of the cancer code to repair or replace missing, mutated or damaged genes. Or simply destroy them entirely. Using a patient’s own cells, the immune system can be reset to battle cancer in the same way the system fights simple illness. And, we can now use manipulated viruses to carry new genes to a tumor, in just the same way a virus invades healthy tissues, but for the good.

In addition, drugs are in development to strangulate a tumor by cutting off its blood supply, or directly destroy cancer stem cells, believed to be the root of disease. Powerful anti-inflammatory agents may be used to facilitate cell death. And, in the not so distant future, an inoculation may make cancer as obsolete as other pandemics.

WHEN?

In this country and across the globe, research studies are paving the way to make cancer a manageable disease like diabetes. Thousands of patients have already been enrolled in trials, and lives have been saved, many when all other options had failed and the prognosis terminal.

For nearly 15 years, Alliance for Cancer Gene Therapy (ACGT) has been dedicated to a totally different paradigm for cancer treatment, and these treatments are becoming a reality. The bow has been drawn and the arrow headed for the bull’s eye. Sooner than you think.

“Fifteen years ago, when we first learned of cell and gene therapies for cancer, we believed that molecular medicine would change everything. Sooner than we even imagined, this science, and new technologies, are changing the way we treat cancer and saving lives.”

– Barbara Netter,
ACGT President and
Co-founder

2015 FELLOWS TARGET IMMUNOLOGY

Two grants this year were made to innovative researchers in the discovery phase.

“Young investigators develop into major investigators and future patients may survive because of their work.”

– Dr. Savio L.C. Woo,
Chairman Emeritus, ACGT Scientific Advisory Council



Meenakshi Hegde, MD

Meenakshi Hegde, MD

Assistant Professor, Department of Pediatric Hematology, Texas Children's Cancer Center at Baylor College of Medicine, Houston

RESEARCH: Immune-mediated treatment for melanoma

Melanoma has been steadily increasing in the last decade – over 76,000 new cases last year alone – and despite improvements

in diagnosis and early stage treatment, patients with late stage, metastatic cancer have less than a 10% prognosis for recovery. Dr. Hegde is aiming her arrow on the use of cancer cells known as antigens, which express tumor-specific molecules used to attack the cancer without affecting healthy cells. The study explores two specific antigens: HER2 and GD2, and hopes to advance findings toward clinical trials.

Dr. Hegde earned an MD at Rajiv Gandhi University of Health Sciences, India, served as pediatric resident at University of Illinois, Chicago, and was a post-doctoral fellow in pediatric hematology and oncology at Baylor College of Medicine, Houston, TX.



Christopher Jewell, PhD

Christopher Jewell, PhD

Assistant Professor, Department of Bio-engineering, University of Maryland, College Park

RESEARCH: Immunology and Inoculation

Dr. Jewell's study focuses on harnessing lymph nodes as therapeutic agents. The goal is to engineer

these tissues to facilitate the immune response, using controlled release vaccines with DNA-encoded molecules commonly found on cancer cells. In this way, treatment will destroy tumors and also establish a barrier to protect against recurrence. This technology is also expected to be useful in establishing a new class of inoculations by shedding light on how cancer vaccine components impact lymph node functions.

Dr. Jewell earned an MS and PhD in Chemical Engineering at University of Wisconsin, as well as a BS at Lehigh University, PA. He also held post-doctorate positions at MIT and Harvard University.

MARKSMEN/WOMEN

NEW STEWARDS



Joseph C. Glorioso, III, PhD



John Bell, PhD



E. Antonio Chiocca, MD, PhD, FAANS

Scientific Advisory Council

Joseph C. Glorioso, III, PhD

Professor of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA, newly elected Chair of ACGT Scientific Advisory Council

John Bell, PhD

Senior Scientist, Cancer Therapeutics Program, Ottawa Hospital Research Institute, 2013-14 ACGT Research Fellow

E. Antonio Chiocca, MD, PhD, FAANS

Neurosurgeon-in-Chief and Chairman, Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, 2007 ACGT Research Fellow

Mitchell H. Finer, PhD

Founder and Senior Consultant, Avalanche Biotechnologies, Menlo Park, CA, Managing Director, MPM Capital, Cambridge, MA

Dario A. Vignali, PhD

Vice-Chair, Department of Immunology and Co-Leader, Cancer Immunology Program, University of Pittsburgh, Pittsburgh, PA



Mitchell H. Finer, PhD



Dario A. Vignali, PhD



Aya Jakobovits, PhD

Board of Directors

Aya Jakobovits, PhD joined both the Board and the ACGT Scientific Advisory Council. She is currently President and CEO of Adicet Bio, Inc., and a venture partner at Orbimed Advisors, LLC, a healthcare-dedicated venture capital firm, and is an accomplished biotech executive and longstanding promoter of scientific innovation. She was the President and founding CEO at Kite Pharma, Inc. and also held executive positions at Agensys, Inc., a subsidiary of Astellas Pharma Inc., where she led research, clinical and corporate development activities. She earned a PhD in Life Sciences and M.S.C in Chemistry at Weizmann Institute of Science, Rehovot, Israel.



TOP ROW LEFT TO RIGHT - A record number of swimmers hit the water for SAA Greenwich-Stamford Open Water Swim; ACGT was presented a check for \$350,000 by Swim Across America team captains, leadership and top fundraisers.

MIDDLE ROW - SAA Greenwich-Stamford co-chair, Lorrie Lorenz, Janel Jorgensen, President & CEO, SAA, Michele Graham, SAA Greenwich-Stamford co-chair; 3 swimmers (2 rookies) join hands as they finish the swim; Barbara Netter, President and Co-founder of ACGT presents Dr. Savio L.C. Woo with the Innovative Leadership Award at the 2015 Award Gala.

BOTTOM ROW - Dr. Savio L.C. Woo, Barbara Netter, President and Co-founder of ACGT, Dr. Joseph Glorioso, Emily Whitehead, Dr. Carl June and Bob Levis; ACGT Scientific Advisory Council member, Dr. Stephen Eck and ACGT Executive Director, Margaret Cianci.

SAA and Gala Photographs by Elaine Ubiña


BOWS AND ARROWS

2015 HAPPENINGS

The 9th annual Greenwich-Stamford Swim Across America to benefit ACGT raised over \$350,000 to fund advanced studies by three ACGT Investigators: Dr. Arnob Banerjee, University of Maryland School of Medicine; Dr. John Bell, Ottawa Research Institute; and Dr. Fan Yang, Stanford School of Medicine. A record number of swimmers and swim teams participated, all honoring a cancer survivor or casualty, and inspired by new event chairs, Michele Graham and Lorrie Lorenz, whose daughters are cancer survivors.

ACGT co-sponsored with University of Pennsylvania a panel on *Innovation and Entrepreneurship Trends* at the **2015 BIO International Convention** in Philadelphia, where ACGT Scientific Advisory Council member Dr. Carl June, whose immunology research has broken new ground treating many forms of cancer, joined a panel discussion with fellow Penn faculty and leading biotech firms about trends in cell and gene therapies. Dr. June was also featured in Ken Burns' 2015 PBS documentary based on "The Emperor of All Maladies: A Biography of Cancer" by Dr. Siddhartha Mukherjee.

Alexander Stegh, PhD, Northwestern University, a 2012 ACGT Research Fellow, reported the results of a study using gold nanoparticles to turn off cancer genes in glioblastoma, a deadly brain cancer. These nanoparticles are able to cross the blood-brain barrier without toxicity and without interference from the immune system, and congregate to regulate cell growth and prolong survival.



"We demonstrate a more specific, more personalized approach to therapy... a platform to silence the particular genes that drive or contribute to cancer progression in individual patients."

– Alexander Stegh, PhD, Northwestern University, 2012-2013 ACGT Research Fellow

Scientists, patients, and supporters celebrated the first **ACGT Innovative Leadership Award Gala** at the Harvard Club, New York City, honoring Dr. Savio L.C. Woo, retiring Founding Chair of ACGT's Scientific Advisory Council. The event raised over \$750,000 for research. Dr. Woo and ACGT co-founders Barbara and Edward Netter agreed nearly fifteen years ago to establish an organization devoted to the research and advancement of cancer gene therapies, then still in their infancy, and now proving to potentially revolutionize cancer care. The gala featured two patients who survived near-fatal battles with leukemia because of clinical trials at University of Pennsylvania based on research funded by ACGT.

On the afternoon preceding the Gala, members of **ACGT's Scientific Advisory Council** gathered at a symposium to confirm the organization's strategic direction to greater emphasize advanced studies leading to clinical trials. The goal is to move the science more rapidly from bench to bedside, and also collaborate with biotech and pharmaceutical companies which have recognized the potential and are thus willing to invest in molecular medicine for cancer.

ACGT FELLOWS IN FAST FLIGHT

“What we do is the ultimate personalized medicine. We start with a patient’s own immune system. White blood cells are removed and in a 5 – 10 day process, we engineer those cells into leukemia-specific killers, although we can now also target these to many cancers.”

– Carl June, MD, University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA



Lieping Chen, MD, PhD

*United Technologies Corporation Professor, Cancer Research, Yale School of Medicine
Founding Member, ACGT Scientific Advisory Council*

Dr. Chen deploys a new generation of antibodies known as PD-inhibitors that block pathways preventing the immune system from combating cancer or protecting against recurrence. This approach is the basis for the drug Keytruda, which received FDA approval to treat advanced melanoma, and Nivolumab and Pembrolizumab, which both recently received FDA approval for multiple solid tumor indications.

Carl June, MD

*Director of Translational Research, Abramson Cancer Center, University of Pennsylvania
Member, ACGT Scientific Advisory Council, 2004, 2008 ACGT Research Fellow*

At the 2015 annual meeting of the American Association for Cancer Research (AACR) Dr. June reported successful interim results of a trial funded by the 2008 ACGT Joan Miller and Linda Bernstein Ovarian Cancer Grant. Patients in Phase I at the Perelman School of Medicine no longer responded to other treatments. They received genetically modified immune cells that successfully attacked pancreatic or ovarian cancers without adverse side effects. Killer T-cells survived and stood guard in the blood stream for up to 28 days, and continued monitoring will evaluate long-term health.

Glenn Dranoff, MD

*Global Head of Exploratory Immunology, Novartis
2010 ACGT Research Fellow*

Dr. Dranoff, a renowned cancer vaccine expert, helped engineer a multiyear alliance with Aduro Biotech to promote discovery and development of next generation immunotherapies targeting the STING (Stimulator of Interferon Genes) pathway, which blocks immune system response to cancer. While Professor of Medicine at Dana-Farber Cancer Institute and Harvard Medical School, Dr. Dranoff developed basic and translational research to explain the cellular and molecular mechanisms underlying anti-tumor immunity.

Michel Sadelain, MD, PhD

*Director, Center for Cell Engineering, Memorial Sloan-Kettering Cancer Center
Member, ACGT Scientific Advisory Council, 2004 ACGT Research Fellow*

Dr. Sadelain assumed the Presidency of the Board of the American Society of Gene and Cell Therapies (ASGCT) devoted to advancement, education and clinical expansion of genetic and cellular therapies. Nearly 2000 scientists and biomedical professionals from 36 countries attended the 2015 annual meeting where many ACGT scientists presented findings and were featured in panel discussions on cancer therapies.



2015 SCORECARD

ACGT FINANCIAL REPORT FISCAL YEARS ENDED APRIL 2014 AND 2015

CONDENSED STATEMENTS OF ACTIVITIES

	2015	2014
Support and revenue:		
Contributions	\$960,174	\$785,961
Contributions for administrative expenses (specially designated)	364,150	279,100
Contributed services	357,585	265,789
Interest and dividend income	102,399	87,795
Realized and unrealized gains on investments, net	160,067	216,559
TOTAL SUPPORT AND REVENUE	\$1,944,375	\$1,635,204
Expenses:		
Program services:		
Research grants and awards	\$1,739,756	\$794,126
Management and general	225,863	188,233
Fundraising	103,799	56,246
TOTAL EXPENSES	2,069,418	1,038,605
(Decrease) increase in total net assets	(125,043)	596,599
Total net assets at beginning of year	3,982,702	3,386,103
TOTAL NET ASSETS AT END OF YEAR	\$3,857,659	\$3,982,702

CONDENSED STATEMENTS OF FINANCIAL POSITION

	2015	2014
Assets:		
Cash and cash equivalents	\$646,150	\$471,784
Contributions receivable, net	-	25,000
Investments, at fair value	4,361,748	4,227,234
Accounts receivable and prepaid expenses	24,055	8,430
TOTAL ASSETS	\$5,031,953	\$4,732,448
Liabilities and net assets:		
Liabilities		
Grants payable	\$1,139,253	\$728,762
Accounts payable and accrued expenses	35,041	20,984
TOTAL LIABILITIES	1,174,294	749,746
TOTAL NET ASSETS	3,857,659	3,982,702
TOTAL LIABILITIES AND NET ASSETS	\$5,031,953	\$4,732,448

Alliance for Cancer Gene Therapy, Inc.'s complete audited financial statements are available upon request.



“They took the T-cells, re-engineered them to kill cancer cells, and it worked. I’m living proof.”

– Bob Levis, Patient in a University of Pennsylvania gene therapy trial based on research funded by ACGT




“In May we celebrated our daughter Emily’s 10th birthday and 3 years cancer free. We are still a family because of what you do.”

– Tom Whitehead, whose daughter was a patient in a University of Pennsylvania/CHOP gene therapy trial for Acute Lymphocytic Leukemia, initially funded by ACGT

BOWSMEN/WOMEN

ACGT RESEARCH FELLOWS

These scientists from prestigious institutions focus their sights on cell and gene therapies for all forms of cancer. Young Investigator Grants award \$250,000 for discovery research to encourage innovation and Clinical Investigator Grants award \$500,000 - \$1,000,000 for advancement of studies leading to clinical trials.



2014-2015

Meenakshi Hegde, MD

Texas Children's Cancer Center, Baylor College of Medicine – Melanoma

Christopher Jewell, PhD

University of Maryland, College Park – Lymph Nodes

2013-2014

Arnob Banerjee, MD, PhD

*Swim Across America Award
University of Maryland School of Medicine – Blood Cancer*

Fan Yang, PhD

*Swim Across America Award
Stanford University School of Medicine – Brain Cancer*

John Bell, PhD

*Swim Across America Award
Ottawa Hospital Research Institute – Brain Cancer*

2012-2013

Douglas Mahoney, PhD

University of Calgary – Breast Cancer

Alexander Stegh, PhD

Northwestern University – Brain Cancer

Herbert J. Zeh, III, MD, FACS

University of Pittsburgh – Pancreatic Cancer

2011

Hui Hu, PhD

University of Alabama – Ovarian Cancer

2010

Nabil Ahmed, MD, MPH

Baylor College of Medicine – Brain Cancer

Glenn Dranoff, MD

*Dana Farber/Harvard Cancer Center (through May 2015)
– Leukemia*

Thomas Kipps, MD, PhD

*Swim Across America Award
Moore's Cancer Center, University of California, San Diego –
Lymphoma/Leukemia*

Michael Z. Lin, MD, PhD

Stanford University – Brain & Breast Cancer

2009

Steve Thorne, PhD

University of Pittsburgh – Breast & Ovarian Cancer

2008

Carl June, MD

*Joan Miller & Linda Bernstein Ovarian Cancer Award
University of Pennsylvania Abramson Cancer Center –
Ovarian Cancer*

2007

E. Antonio Chiocca, MD, PhD

Brigham and Women's Hospital – Brain Cancer

Ronald Levy, MD


Stanford University – Lymphoma


Clodagh O'Shea, PhD

Salk Institute for Biological Studies – Breast Cancer

Khalid Shah, PhD, MSc

*Swim Across America Award
Harvard Medical School, Massachusetts General Hospital –
Brain Cancer*





2006

Roberto Cattaneo, PhD

Mayo Clinic College of Medicine – Lymphoma/Leukemia

George Coukos, MD, PhD

*The Dr. Judah Folkman Anti-angiogenesis Award
University of Pennsylvania Abramson Cancer Center
– Ovarian & Peritoneal Cancer*

Maciej S. Lesniak, MD

University of Chicago – Brain Cancer

Kah-Whye Peng, PhD

Mayo Clinic Cancer Center – Multiple Myeloma

Eckhard Podack, MD, PhD

University of Miami Miller School of Medicine – Lung Cancer

Harald Sauthoff, MD

New York University – Breast/Lung Cancer

2005

Biao He, PhD

University of Georgia – Breast Cancer

Thomas J. Kipps, MD, PhD

*Swim Across America Award
Moore's Cancer Center, University of California, San Diego –
Lymphoma/Leukemia*

Hyam I. Levitsky, MD

*Juno Therapeutics, Johns Hopkins University School of Medicine –
Lymphoma/Leukemia*

Miguel Sena-Esteves, PhD

University of Massachusetts Medical School – Brain Cancer

Koji Tamada, MD, PhD

University of Maryland – Lymphatic Systems

Yiping Yang, MD, PhD

Duke University Medical Center – Lymphoma/Leukemia

Xianzheng Zhou, MD, PhD

New York Medical College – Blood Cancer, Lymphoma/Leukemia

2004

Chien-Fu Hung, PhD

Johns Hopkins University School of Medicine – Ovarian Cancer

Mukesh Jain, MD, FAHA

Case Western Reserve University – Metastatic Cancer

Carl H. June, MD

*University of Pennsylvania Abramson Cancer Center –
Lymphoma/Leukemia*

Suzie Pun, PhD

*Patricia Zoch Tate Award
University of Washington – Metastatic Cancer Delivery*

Michel Sadelain, MD, PhD

*Memorial Sloan-Kettering Cancer Center –
Lymphoma/Leukemia*

Jian Yu, PhD

*University of Pittsburgh School of Medicine, Hillman Cancer
Center – Lung Cancer*

2003

Laurence Cooper, MD, PhD

MD Anderson Cancer Center – Lymphoma/Leukemia

Timothy Lane, PhD

*The Kimberly Lawrence Netter Breast Cancer Award
University of California, Los Angeles – Breast Cancer*

Todd R. Reilly, PhD

Johns Hopkins University (through 2006) – Breast Cancer

Katherine Ryman, PhD

*University of Pittsburgh, Center for Vaccine Research –
Prostate Cancer*

Robert Vonderheide, MD, DPhil

*University of Pennsylvania Abramson Cancer Center –
Neuroblastoma*

2002

Jeffrey S. Bartlett, PhD

Callimmune, Inc. – Ovarian Cancer

Andrew M. Davidoff, MD

St. Jude Children's Research Hospital – Neuroblastoma

Thomas S. Griffith, PhD

University of Minnesota – Prostate Cancer

We invite you to read more about ACGT Fellows online at www.acgtfoundation.org/grants-and-research/acgt-fellows/

SHARPSHOOTERS

ACGT SCIENTIFIC ADVISORY COUNCIL

With a wide range of backgrounds – from biotech and pharma to academic institutions – council members take aim at the most promising research, monitor progress, and provide insight into potential partnerships to advance molecular medicine.

Joseph C. Glorioso III, PhD, Chairman, Scientific Advisory Council

*Professor of Microbiology and Molecular Genetics,
University of Pittsburgh School of Medicine, Pittsburgh, PA*

Stuart A. Aaronson, MD

Jane B. and Jack R. Aron Professor and Chairman Department of Oncological Sciences, Mount Sinai School of Medicine, New York, NY

John Bell, PhD

Senior Scientist, Cancer Therapeutics Program, Ottawa Hospital Research Institute, Canada

Xandra O. Breakefield, PhD

*Professor, Department of Neurology, Harvard Medical School, Geneticist,
Molecular Neurogenetics Unit, Massachusetts General Hospital, Boston, MA*

Lieping Chen MD, PhD

*United Technologies Corporation Professor in Cancer Research, Professor of Immunobiology,
Dermatology and Medicine Director, Cancer Immunology Program,
Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT*

E. Antonio Chiocca, MD, PhD, FAANS

*Neurosurgeon-in-Chief and Chairman, Department of Neurosurgery,
Brigham and Women's Hospital, Boston, MA*

Stephen L. Eck, MD, PhD

Vice President, Global Oncology Astellas Pharma US, Inc., Global Development, Deerfield, IL

Mitchell H. Finer, PhD

*Founder and Senior Consultant, Avalanche Biotechnologies, Menlo Park, CA;
MPM Capital, Managing Director, Cambridge, MA*

Aya Jakobovits, PhD

*President and CEO, Adicet Bio, Inc. Beverly Hills, CA;
Venture Partner, Orbimed Advisors, LLC, New York, NY*

“Targeted therapies leave the patient intact, without the toxicity of conventional therapies that harm normal tissue. Patients benefit with great outcomes.”

– John Bell, MD, Senior Scientist, Cancer Therapeutics Program, Ottawa Hospital Research Institute, Canada ACGT Scientific Advisory Council, 2013-2014 ACGT Research Fellow

Carl H. June, MD

Richard W. Vague Professor in Immunotherapy, Pathology and Laboratory Medicine, Director of Translational Research Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

Michael T. Lotze, MD

Professor of Surgery & Bioengineering, Vice Chair Research, Department of Surgery, Director, Strategic Partnerships, University of Pittsburgh Cancer Institute, Pittsburgh, PA

Jack A. Roth, MD, FACS

Professor and Bud Johnson Clinical Distinguished Chair, Chief, Section of Thoracic Molecular Oncology, Professor of Molecular & Cellular Oncology, Director, W.M. Keck Center for Innovative Cancer Therapies, The University of Texas MD Anderson Cancer Center, Houston, TX

Stephen J. Russell, MD, PhD

Director, Molecular Medicine Program, Consultant, Department of Hematology, Professor of Medicine, Mayo Clinic, Rochester, MN

Michel Sadelain, MD, PhD

Director, Center for Cell Engineering, Stephen and Barbara Friedman Chair, Memorial Sloan-Kettering Cancer Center, New York, NY

Dario A. Vignali, PhD

Vice-Chair, Department of Immunology and Co-Leader, Cancer Immunology Program, University of Pittsburgh, Pittsburgh, PA

George D. Yancopoulos, MD, PhD

President, Regeneron Laboratories and Chief Scientific Officer, Regeneron Pharmaceuticals, Inc., Tarrytown, NY

Savio L.C. Woo, PhD

Chairman Emeritus



EXPERTS

ACGT BOARD OF DIRECTORS

Leaders in the field provide strategic direction and oversight to the quality and integrity of our organization and the delivery of our mission.

Barbara Netter, MS

*President and Co-founder
Psychotherapist, Greenwich, CT*

Edward Netter (In Memoriam)

Founding President (2001-2011)

David M. Darst

Chief Executive Officer, RGENIX, Inc, New York, NY

Peter A. Glicklich, Esq.

*Managing Partner, Davies, Ward,
Phillips & Vineberg, LLP, New York, NY*

Peter C. Hearn

Insurance Industry Executive, New York, NY

Tracy Bishop Holton

Attorney and Author, Greenwich, CT

Aya Jakobovits, PhD

*President and CEO, Adicet Bio, Inc. Beverly Hills, CA;
Venture Partner, Orbimed Advisors, LLC, New York, NY*

Jeffrey C. Keil

Chairman, Executive Committee, Knight Vinke, New York, NY

John L. Lahey, PhD

President, Quinnipiac University, Hamden, CT

Alexandra N. Landes

Founder and Executive Director, Wendy Walk, Pacific Palisades, CA

Sharon Walsted Phillips

Not-for-Profit Consultant, Greenwich, CT

John Reinsberg

Deputy Chairman, Lazard Asset Management, LLC, New York, NY

John C. Sites, Jr.

Partner, Wexford Capital, LLC, Greenwich, CT

Martin Winter

Managing Director, Alvarez & Marsal, New York, NY

Martha Zoubek

President, Wrightson-Ramsing Foundation, Greenwich, CT

We express our sincerest gratitude to these retiring ACGT leaders for their dedication of time and energy to the development of cell & gene therapies for cancer.

Daniel W. Cummings

*ACGT Board of Directors
Harvard Management Co. MA*

Robert L. Martuza, MD, FACS

*ACGT Scientific Advisory Council
Harvard Medical School, MA*

John Nemunaitis, MD

*ACGT Scientific Advisory Council
Mary Crowley Medical Research Center, TX*

Drew M. Pardoll, MD, PhD

*ACGT Scientific Advisory Council
Johns Hopkins University School of Medicine, MD*

Eric A. Rothfeld

*ACGT Board of Directors
REI Capital, NY*

Swan Thung, MD

*ACGT Board of Directors
Mount Sinai Medical Center, NY*

Thomas J. Wickham, PhD

*ACGT Scientific Advisory Council
Merrimack Pharmaceuticals, MA*

CHAMPIONS

ACGT CORPORATE SUPPORT

\$50,000 +

Geneve Corporation
KPMG

\$25,000 TO \$49,999

Davies Ward Phillips & Vineberg LLP
Quinnipiac University
Willis Group

\$10,000 TO \$24,999

D.W. Van Dyke & Co., Inc.
Duff and Phelps
Kramer, Levin, Naftalis, and Frankel LLP
Robinson + Cole LLP
University of Massachusetts Medical School

\$5,000 TO \$9,999

CIGNA
Eisner Amper LLP
Independence Holding Company
National Insurance Services
Quarles & Brady LLP
Robert A. Welke Cancer Research Foundation -
Links to a Cure
Standard Security Life Insurance Company
of New York
Towers Watson


\$1,000 TO \$4,999

Brown Smith Wallace, LLC
Crane Co.
JP Morgan Chase
Lindquist Garden Design
Tisch Cancer Institute - Mt. Sinai School of Medicine
TRU Services, LLC
XL Reinsurance

UNDER \$1,000

American Livery
Co-Communications
CSL Behring
Insurance Compliance Consultants
Tara Frammer Design

Every penny donated to ACGT goes directly to research, and many of these studies attract additional or matching grants from institutions and/or government sources.



CHAMPIONS

ACGT INDIVIDUAL SUPPORT

“Cell and gene therapies are moving forward largely because of private funding. Join us. Stay with us. Thank you for your support.” – Joshua Corday, ACGT Senior Development Officer

\$50,000 +

Anonymous
Mrs. Barbara Netter
Swim Across America
Wendy Walk

\$25,000 TO \$49,999

Mr. and Mrs. Bill Fitzgerald
Mr. Peter C. Hearn
Mr. and Mrs. John Sites
The Lapin Foundation

\$10,000 TO \$24,999

Calvin and Marisa Allen
Foundation
Mr. Silas Chou
Cogan Family Foundation
Mr. and Mrs. Daniel
Cummings
Mr. and Mrs. Alan Englander
Mary Henry and
Howard Rubin
Alice Kaplan and
Jason Aronson
Mr. and Mrs. Shau-Wai Lam
Mr. and Mrs. Edward Lampert
Mr. and Mrs. Ezra Levin
Mr. and Mrs. Barnet Phillips
Mr. and Mrs. Reuben Mark
Mr. and Mrs. John Rosenwald

Dr. Swan and Mr. Roy Thung
Mr. Tom Tryforos
The Wasily Family
Foundation
Mr. and Mrs. Robert Weisman
Mr. and Mrs. Martin Winter
Dr. George Yancopoulos

\$5,000 TO \$9,999

Anonymous
Mr. and Mrs.
David M. Darst, Jr.
Mr. and Mrs. Jeb Embree
Julia and Dan Englander
Mr. Peter Glicklich
Joanna Karatzas and
Philip Enquist
Mr. Jeffrey Keil
The Ernest and Joan Liu
Foundation
Mr. John Miller
Sandy and Morton Porwick
Mr. and Mrs. John Reinsberg
Andrew Sabin Family
Foundation
S&L Marx Foundation
Dr. Savio L.C. Woo
Mr. and Mrs. Charles Zoubek

\$1,000 TO \$4,999

Mr. Steven C. Annus
Mr. and Mrs. Grant Behrman
Mr. and Mrs. Allan Bernard
James and Victoria Chang
Family Foundation
Nat and Lucy Day
Mr. Martin Dickman
Ms. Nancy Duffy
Ms. Pamela Duke
Mr. Michael Englander
Mr. and Mrs. John Ferguson
Arline and Paul Gardner
Pam and Bob Goergen
Mr. and Mrs. Carl A. Goldman
Mr. and Mrs. Larry R. Graber
Eugene and Emily Grant
Family Foundation
Robert and Nancy Gregory
Ms. Sarah Wolf and
Mr. Charles Hallac
(posthumously)
Dr. Sandra and
Mr. Ira Harkavy
John and Kelly Hartman
Foundation
Terry and Henry Herbert
Tracy and Mark Holton
James and Victoria James
Family Foundation

The Charles and Ann
Johnson Foundation
Mr. and Mrs. Dean Johnson
Mr. Michael Kemp
Anne and Chau Khuong
Mr. and Mrs. Andrew Kramer
Dr. and Mrs. John Lahey
Mr. and Mrs. Robert M.
Leopold
Susan and Bob Levis
Ms. Karen Li
Ms. Joyce Light
Mr. and Mrs. Brian Lindquist
Ms. Rachel Lipari
Mr. James Mack
Mr. and Mrs. Douglas Moffitt
Ms. Danielle Pinet
Mr. and Mrs. Richard Radcliffe
David Raizen
Roy R. Raizen
Mrs. Francine Roberson
Mrs. Mildred Rosenberg
The Scrivan Family
Foundation
Jill and Robert Serling
Families
Mr. Robert Shasha
Elizabeth and David Sherman
Mr. and Mrs. Richard Silver
Jill and Sandy Sirulnick
Mr. and Mrs. Eric R. Smith

ACGT INDIVIDUAL SUPPORT (CONTINUED)

“The summer of 2010 I was 65 and I didn’t think I’d see Christmas.”

– Bill Ludwig, having run out of options to treat Chronic Lymphocytic Leukemia, was one of the first patients in University of Pennsylvania gene therapy trials. He is 5-years cancer free.

Mrs. Sarah A. Thomas and
Mr. H. William Smith
Dr. and Mrs. Robert Soley
Mr. and Mrs. Henry Spencer
Dr. Kathleen Van Cleef-Toedt
Mr. Michael Tong
Mr. and Mrs. Charles Tusa

UNDER \$1,000

Anonymous
Mrs. Maxine Armstrong
Mr. Robert M. Arnold
The Arnsten Foundation, Inc.
Drs. Bonnie and
Arthur Ashman
Mr. and Mrs. Lionel Bandler
Ms. Lucy R. Banker
Mr. and Mrs. Gilbert Bassin
Ms. Claudia M. Beard
Mr. and Mrs. John Bennett
Ms. Janaura Bishop
Ms. Deborah Block
Ms. Diana Block

Mr. and Mrs. Andre Block
Ms. Elsie Bloom
Mr. Jeremy Bradshaw
Mr. Robert J. Brady
Hugh and Carmen Bridgford
Mr. Fred Brooks
Mr. Brian David Brown
Mr. Christoph Burkart
Mr. Charles Carlson
Mr. Jonathan Frank Carlson
Mr. Rob F. Cashel
Mr. Don Cates
Mr. John D. Chalk III
Mr. and Mrs. Robert Chandler
Margaret and Jeff Cianci
Mr. Joseph Cianci
Ms. Joy Cianci
Mrs. Stephanie Cohen
Mr. and Mrs. John Condon
Ms. Nancy Costa
Karen and Robert Cagnolin
Ms. Sheila Craig
Mr. and Mrs. James Crowley

Mr. and Mrs. Peter Crumbine
Mr. and Mrs. James Davidson
Ms. Patricia Dawson
Mrs. Joanne Delle Cave
Ms. Sandra Jean DePompa
Ms. Beth Carol Diehl-Svrjcek
Venkat Dinavahi
Ms. Helen Dixon
Ms. Maureen Downie
Ms. Martha Droge
Mr. Eugene Eanes
Ms. Bethea Eichwald
Dr. and Mrs. Robert S. Fields
Dr. Heidi and Mr. Chris Flagg
Mr. James Fogarty
Heather and Dulany Foster
Ms. B. Fuchs
Ms. Kathryn Gabler
Ms. Michele D’Angelo Garvey
Mr. Christopher Gay
Jo Ann and Gordon Gaynor
Mr. Richard Gendelman
Mr. Ronald P. Genuario
Mrs. Anne Gilhuly
Mrs. Barbara Burke
Southerland Gilliam
Ms. Deanna Gilman
Ms. Alyssa Goduti
Ms. Mary Godzeno

Arline and Richy
Diamant Gold
Ms. Florence Goldstein
Mr. and Mrs. Terry Goodwin
Mr. and Mrs. Sheldon Gordon
Ms. Judith Gotsdiner
Mr. Jonathan P. Gottlieb
Dr. Peter B. Griffin
Mr. John Griswold
Mr. David Grossman
Ms. Brenda Patton Hacklin
Reva and Jesse Halperin
Dr. John P. Hanson
Dr. Lyn and
Mr. Robert Harmon
Mr. and Mrs. William Hart, Jr.
Ms. Barbara Hayes
Mrs. Jean Heller
Mr. Andreas Henke
Ms. Kellie Hepler
Ms. Karen Hsu
Mr. and Mrs. Thomas Hughes
Ms. Cheryl Hurwitz
Ms. Susan Hut
Mr. Kenneth Irvine
Mr. Walter Jenkins
Carol and Steve Johnson
Ms. Laurie Josephs and
Mr. Josh Brain

“I really do believe victory is close at hand and I am hopeful we can change cancer from a dreaded, life-threatening disease to something we can eradicate together.”

– Dr. Thomas Kipps, MD, PhD, Moores Cancer Center, University of California, San Diego, ACGT Research Fellow

“We’re entering the modern era, and through a renaissance, in how local immune response will lead to a systemic immune response; the eradication of tumors in one site will lead others going away.”

– Michael T. Lotze, MD, University of Pittsburgh Cancer Institute,
ACGT Scientific Advisory Council

Mr. H. Steven Kanofsky
Mr. and Mrs. Stuart Kaplan
Mr. and Mrs. John Kelly
Mr. Paul Kempner
Mr. Thomas Kerrigan
Mr. and Mrs. David Kettig
Ms. Maryln Kimmel
Mr. and Mrs. Edwin Kirsch
Ms. Carol A. Klimek
Ms. Lysa Randolph Kraft
Ms. Alexandra Landes
Linda and Irwin Lefkowitz
Jodi and Kenneth Levine
Mr. and Mrs. Steven Levy
Mr. Martrevus
De-Vaughn Lewis
Mr. and Mrs. Brian Lindquist
Mr. Theodore Lobsenz
Carolyn and James Lockhart
Mr. and Mrs. Walter Lorenz
Ms. Jessica Lyon
Mr. Richard Malnight
Ms. Joanne Marien
Ms. April Lynn Martin
Ms. Sheila E. Martin
Mr. Thomas L. Martin
Rebecca and Brett Matzek

Barbara and
Timothy McCluskey
Ms. Leslie Ann McDonald
Mr. and Mrs. James Mendler
Mr. and Mrs. Juan Meyer
Cliff and Joyce Millian
Mr. William Mulert
Mr. Paul Mylander
Mr. and Mrs. Joseph Nadan
Mr. Stanley Newmark
Ms. Elizabeth Norris
Mr. Denis O’Brien
Mr. and Mrs. Peter O’Brien
Mr. Ron Ongaro
Ms. Larisa A. Osborne
Ms. Dianne Ostroski
Mr. Ken Parmalee
Ms. Kathryn Payne
Mr. and Mrs. Staats Pellett, Jr.
Perkins Charitable
Foundation
Ms. Leigh H. Perkins
Mr. and Mrs. Myron Picoult
Dr. Beth and
Mr. Jordan Posner
Mr. William Pritz
Ilse and Paul Puri
Ms. Barbara L. Pusert

Ms. Lorraine Reardon
Mr. and Mrs. Ronald Reiss
Ms. A. Gloria Ricco
Mr. and Mrs. Steve Rippon
Mr. and Mrs. Robert Ritter
Ms. Deborah Rivers
Leonardo P. Rizzuto
Mr. and Mrs. Victor Romley
Mr. and Mrs. John Rosenberg
Sandra and
Dennis Rosenzweig
Mr. and Mrs. Richard Rupp
Faith and Philip Ruppel
Mr. and Mrs. Eric Ryzerski
Ms. Mary Sacchetillo
Nancy and Stephen Sahlein
Mr. Robert Schermer
Mr. and Mrs. Brian R. Schlier
Phyllis and Jay Schondorf
Mr. and Mrs. Bobeck
Shayegani
Mr. Jerry Shields
Ms. Lilian Sicular
Hope and Harold Simkowitz
Mr. Jeffrey Simmonds
Mr. and Mrs. Alan Simon
Anne and Ronald Simon
Mr. and Mrs. Robert Slatkin
Joanne and Chris Stavrou
Ms. Marilyn Stein
Mrs. Nancy Stillerman
Mr. Peter Sutton
Mr. and Mrs. C. Winfield Swarr
Donna and Scott Tagliarino
Mr. and Mrs. James G. Tatum

Edna and Larry Ter Molen
Ms. Virginia D. Thomas
Karen and Doug Thomson
Dr. Deborah and The
Honorable Richard Tolchin
Mr. and Mrs. Paul Toretta
Ms. Yvonne Tropp
Mr. and Mrs. Charles Tusa
Mr. and Mrs. Kevin Tyburski
Ms. Janice Valukas
Mr. and Mrs. Dennis
van de Hey
Mr. Karl Von Batsch
Mr. and Mrs. Matt Vossler
Mr. Thomas Walmsley
Mr. Austin James Warrin
Mr. Michael Warring
Ms. Judith E. Weber
Richard and Mary Weinstock
Mr. and Mrs. Scott Welsh
Marylu and Jack Williams
Carol and Donald Young
Ms. Barbara Zwick

We have made every effort to ensure the accuracy of our donor listings. If your name has been omitted or misprinted, please accept our sincere apologies and notify us by email at jcorday@acgtfoundation.org or call Joshua Corday at 203.358.5055.

ACGT STAFF

Margaret C. Cianci

Executive Director

Joshua Corday

Senior Development Officer

H. William Smith

Legal/Secretary

Christine A. Herman

Finance/Treasurer

Jill Smith

Foundation Administrator

Phyllis Schondorf

Outreach Coordinator

Writer: Randy Kraft

Design: Tara Frammer Design

“Cell and gene therapies work, and nothing proves this more than the incredible advancement of the science in such a short time – a reflection of the profound impact of molecular medicine, dedicated research and sustained funding. The time is now.”

– Margaret C. Cianci,
ACGT Executive Director



CONTACT ACGT

Margaret Cianci, Executive Director
mcianci@acgtfoundation.org
203.358.5055

SPREAD THE WORD


facebook.com/acgtfoundation
@ACGTFoundation
youtube.com/acgtfoundation

A <ADENINE>

G <GUANINE>

C <CYTOSINE>

T <THYMINE>




ACGT IS THE
ONLY CHARITABLE
ORGANIZATION IN THE
COUNTRY DEDICATED
EXCLUSIVELY TO
CELL AND GENE
THERAPY RESEARCH
FOR CANCER.



Discovering new ways to treat and defeat cancer

Ninety-six Cummings Point Road
Stamford, Connecticut 06902

Non Profit Org.
U.S. Postage
PAID
Stamford, CT
Permit No. 12



EFFICIENT > 100% of contributions go directly to medical research as a Board fund covers all administrative expenses.

RIGOROUS > Research proposals must meet highly-selective criteria for funding.

FOCUSED > Funding is aimed at high-potential projects to optimize research results.

COLLABORATIVE > We engage with research institutions, foundations and corporate partners to maximize results.

SELECTIVE > Donors have the option to invest in specific types of cancer or treatment.

www.acgtfoundation.org